Mixed Dyslipidemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mixed Dyslipidemia – Drugs In Development, 2024 report and make more profitable business decisions.
Dyslipidemia is a condition where the lipid levels in blood are either low or high. While in mixed dyslipidemia the levels of LDL (low density lipoprotein) and TG (triglycerides) are elevated, and HDL (high density lipoprotein) is low. This occurs when there is an overproduction of very low-density lipoprotein (VLDL) leading to an increase in LDL and TG. People with mixed dyslipidemia are at risk of developing coronary heart disease (CHD) and atherosclerosis. It is prevalent in 0.5 to 8.8 % of the general population. Underlying diseases, genetic inheritance, age, obesity, and alcohol abuse are common factors associated with this condition. Diagnosed by lipid profile test (LPD) where the levels are assessed. Statins are the first line of therapy and then bile acid sequestrants, fibrates, and a healthy diet are recommended.
The Mixed Dyslipidemia drugs in development market research report provide comprehensive information on the therapeutics under development for Mixed Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mixed Dyslipidemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mixed Dyslipidemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 10 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mixed Dyslipidemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mixed Dyslipidemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mixed Dyslipidemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Addpharma IncArrowhead Pharmaceuticals Inc
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Daewon Pharmaceutical Co Ltd
Dongkwang Pharma Co Ltd
Eli Lilly and Co
Guangzhou Jiayue Pharmaceutical Technology Co Ltd
Shanghai Junshi Biosciences Co Ltd
Visirna Therapeutics HK Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Mixed Dyslipidemia reports